NEXUS AG

Latest Results (21.01.2026):

NEXUS AG — third quarter 2024 (reporting period 01/01/2024–30/09/2024): the company reported strong nine‑month results in its Q3 2024 statement with revenue up 11.4% to KEUR 190,805, EBITDA rising 15.2% to KEUR 40,856 and consolidated net income up 16.0% to KEUR 20,267 (earnings per share EUR 1.18). The report presents operating strength across segments, higher recurring maintenance revenue, continued investment in software (capitalized development KEUR 3,270) and several post‑period acquisitions to expand diagnostics and laboratory capabilities.

Top‑line and profitability

Sales (01/01–30/09/2024) KEUR 190,805 (+11.4% vs 9M‑2023). EBITDA KEUR 40,856 (+15.2%), EBIT KEUR 27,179 (+21.6%), EBT KEUR 28,034 (+18.3%) and consolidated net income KEUR 20,267 (+16.0%). Undiluted EPS rose to EUR 1.18 (+15.7%).

Segment performance

NEXUS/DE segment revenues KEUR 63,723 (+12.6%); NEXUS/DIS KEUR 51,482 (+29.1%); NEXUS/ROE KEUR 86,677 (+4.3%). The company notes organic growth would have been ~8.1% (sales) and ~20.3% (EBIT) excluding this year's acquisitions.

Revenue mix

Recurring maintenance and other recurring revenue KEUR 104,043 (+17.8%) drove stability; services KEUR 48,825 (+10.0%); licenses roughly flat at KEUR 26,710. For the quarter (Q3 portion) total sales KEUR 63,140 (+6.3% vs Q3‑2023).

Regional trends

Germany grew strongly (+18.7% to KEUR 107,423). Switzerland/Liechtenstein +8.4% (KEUR 41,307). Netherlands +5.4%, Austria +23.6%; Poland and France showed softer development (Poland -22.8%).

Cash, cash flow and balance sheet

Operating cash flow for 9M KEUR 27,716 (‑4.9% YoY), reduced mainly by higher tax payments and increases in receivables; the company states that without the high tax payments cash flow would have been ~MEUR 32 (+~10%). Cash and short‑term financial assets total KEUR 102,543. Total assets KEUR 415,345 (+3.9% vs 30/09/2023) and equity KEUR 269,205.

Investments and capitalization

Investments in tangible/intangible assets KEUR 5,643 (9M), including capitalized software development KEUR 3,270 (+21.8% YoY). Total depreciation KEUR 13,677.

Costs, integrations and one‑offs

Integration costs for acquired companies in 2024 amounted to KEUR 2,021. Currency effects (stronger CHF and PLN) added KEUR 1,913 to sales and KEUR 379 to EBITDA. The report notes consolidation effects from prior‑year acquisitions are included in results.

Acquisitions and post‑period events

No acquisitions during the 9M period, but several ownership consolidations occurred. After 30/09/2024 Nexus announced purchases including HD Clinical Ltd. (UK & Ireland) acquired 01/10/2024 and an asset deal for LABSOFT (Spain) on 22/10/2024 — expected to deliver product and cost synergies and expand endoscopy/cardiology and lab offerings.

Operational position and outlook

Headcount averaged 1,853 employees (+13% YoY). Management highlights continued demand for hospital digitization (KHZG and HIS replacement tenders), focus areas including patient journey, AI integration and diagnosis standardization, and a stated objective to remain bold on investments while improving margins.